{"id":"W2981839573","doi":"10.1093/annonc/mdz295","title":"Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a PD-L1 expression level of ≥1% by the USA Food and Drug Administration","year":2019,"lang":"en","type":"editorial","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Pembrolizumab; Medicine; Lung cancer; Chemotherapy; Oncology; Internal medicine; Pemetrexed; Cancer; Immunotherapy; Cisplatin","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0556425,0.001240797,0.002402181,0.002536097,0.004577256,0.009125482,0.006139791,0.03539781,0.01201963],"category_scores_gemma":[0.07464025,0.001244515,0.00426379,0.0021062,0.002671593,0.00577502,0.00628147,0.03344587,0.009337518],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.006131132,"about_ca_system_score_gemma":0.04332951,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.008040555,"about_ca_topic_score_gemma":0.01134439,"domain_scores_codex":[0.9700161,0.008861139,0.004619964,0.002776374,0.009547165,0.00417927],"domain_scores_gemma":[0.9219193,0.01717667,0.00556911,0.002366513,0.03569478,0.01727359],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00009891248,0.00003973297,0.0006441677,0.0003436177,0.0000612059,0.0002881947,0.0002212476,0.0001169783,0.0006132179,0.001852047,0.9556586,0.04006211],"study_design_scores_gemma":[0.0001074036,0.00005889538,0.0009441045,0.001581991,0.0001076348,0.0003435774,0.0003496898,0.0002283751,0.0004805624,0.00303901,0.9926857,0.00007306457],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"editorial","genre_scores_codex":[0.000985686,0.01357539,0.002422516,0.908537,0.05708442,0.0005494666,0.0006580214,0.0001328373,0.01605482],"genre_scores_gemma":[0.02637608,0.01745548,0.01736941,0.8382422,0.0577243,0.00129445,0.001895948,0.0003476372,0.0392944],"genre_candidate":"editorial","genre_consensus":null,"teacher_disagreement_score":0.0556425,"threshold_uncertainty_score":0.2942692,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06686532430890642,"score_gpt":0.3997437970675532,"score_spread":0.3328784727586468,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}